FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978331365> ?p ?o ?g. }

• W1978331365 endingPage "2436" @default.
• W1978331365 startingPage "2428" @default.
• W1978331365 abstract "Purpose Amplification of the HER-2/neu and topoisomerase IIα (TOP2A) genes has been linked to the effects of anthracyclines. Their role in predicting the outcome of anthracycline-based adjuvant chemotherapy for breast cancer patients has remained controversial. Patients and Methods The present substudy of the Scandinavian Breast Group trial 9401, in which an epirubicin-based regimen (nine courses of tailored and dose-escalated fluorouracil, epirubicin, and cyclophosphamide [FEC]) was compared with three or four courses of standard FEC followed by bone marrow–supported high-dose chemotherapy (cyclophosphamide, thiotepa, and carboplatin), included high-risk breast cancer patients (with eight or more positive axillary lymph nodes or at least five nodes with additional poor prognostic indicators). Amplification of HER-2/neu was determined retrospectively in paraffin-embedded tumor tissue sections by chromogenic in situ hybridization. TOP2A was tested only in HER-2/neu–amplified tumors. Results HER-2/neu amplification alone, which was present in 32.7% of the tumors, was a strong prognostic factor for short relapse-free (P = .0034) and overall survival (P = .0008) but showed no direct association with treatment assignment. TOP2A coamplification, which was present in 37% of HER-2/neu–amplified tumors, was associated with better relapse-free survival in patients treated with tailored and dose-escalated FEC (hazard ratio [HR] = 0.45; P = .049). A statistical multivariate Cox's regression analysis confirmed the predictive significance of TOP2A coamplification (HR = 0.30; P = .020) in HER-2/neu–amplified tumors. There was no such association in patients with HER-2/neu–amplified tumors without TOP2A gene amplification. Conclusion Coamplification of HER-2/neu and TOP2A may define a subgroup of high-risk breast cancer patients who benefit from individually tailored and dose-escalated adjuvant anthracyclines." @default.
• W1978331365 created "2016-06-24" @default.
• W1978331365 creator A5011436481 @default.
• W1978331365 creator A5016053082 @default.
• W1978331365 creator A5019482225 @default.
• W1978331365 creator A5024630405 @default.
• W1978331365 creator A5050715526 @default.
• W1978331365 creator A5059334301 @default.
• W1978331365 creator A5065355046 @default.
• W1978331365 creator A5068108014 @default.
• W1978331365 creator A5071571360 @default.
• W1978331365 date "2006-06-01" @default.
• W1978331365 modified "2023-10-16" @default.
• W1978331365 title "Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in <i>HER-2/neu</i>–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401" @default.
• W1978331365 cites W1882532563 @default.
• W1978331365 cites W1896390601 @default.
• W1978331365 cites W1970797634 @default.
• W1978331365 cites W1976052438 @default.
• W1978331365 cites W1977247044 @default.
• W1978331365 cites W1984328080 @default.
• W1978331365 cites W1993275731 @default.
• W1978331365 cites W2001624468 @default.
• W1978331365 cites W2007160568 @default.
• W1978331365 cites W2017888462 @default.
• W1978331365 cites W2030796899 @default.
• W1978331365 cites W2035332337 @default.
• W1978331365 cites W2044230523 @default.
• W1978331365 cites W2089523712 @default.
• W1978331365 cites W2096471659 @default.
• W1978331365 cites W2117115931 @default.
• W1978331365 cites W2133714238 @default.
• W1978331365 cites W2135800076 @default.
• W1978331365 cites W2138991012 @default.
• W1978331365 cites W2157524247 @default.
• W1978331365 cites W2164789874 @default.
• W1978331365 cites W2314318352 @default.
• W1978331365 cites W4322716809 @default.
• W1978331365 doi "https://doi.org/10.1200/jco.2005.02.9264" @default.
• W1978331365 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16682728" @default.
• W1978331365 hasPublicationYear "2006" @default.
• W1978331365 type Work @default.
• W1978331365 sameAs 1978331365 @default.
• W1978331365 citedByCount "233" @default.
• W1978331365 countsByYear W19783313652012 @default.
• W1978331365 countsByYear W19783313652013 @default.
• W1978331365 countsByYear W19783313652014 @default.
• W1978331365 countsByYear W19783313652015 @default.
• W1978331365 countsByYear W19783313652016 @default.
• W1978331365 countsByYear W19783313652017 @default.
• W1978331365 countsByYear W19783313652018 @default.
• W1978331365 countsByYear W19783313652019 @default.
• W1978331365 countsByYear W19783313652020 @default.
• W1978331365 countsByYear W19783313652021 @default.
• W1978331365 countsByYear W19783313652022 @default.
• W1978331365 countsByYear W19783313652023 @default.
• W1978331365 crossrefType "journal-article" @default.
• W1978331365 hasAuthorship W1978331365A5011436481 @default.
• W1978331365 hasAuthorship W1978331365A5016053082 @default.
• W1978331365 hasAuthorship W1978331365A5019482225 @default.
• W1978331365 hasAuthorship W1978331365A5024630405 @default.
• W1978331365 hasAuthorship W1978331365A5050715526 @default.
• W1978331365 hasAuthorship W1978331365A5059334301 @default.
• W1978331365 hasAuthorship W1978331365A5065355046 @default.
• W1978331365 hasAuthorship W1978331365A5068108014 @default.
• W1978331365 hasAuthorship W1978331365A5071571360 @default.
• W1978331365 hasBestOaLocation W19783313651 @default.
• W1978331365 hasConcept C121608353 @default.
• W1978331365 hasConcept C126322002 @default.
• W1978331365 hasConcept C143998085 @default.
• W1978331365 hasConcept C2776694085 @default.
• W1978331365 hasConcept C2776755627 @default.
• W1978331365 hasConcept C2776802502 @default.
• W1978331365 hasConcept C2778239845 @default.
• W1978331365 hasConcept C2780835546 @default.
• W1978331365 hasConcept C2781413609 @default.
• W1978331365 hasConcept C2781451048 @default.
• W1978331365 hasConcept C530470458 @default.
• W1978331365 hasConcept C71924100 @default.
• W1978331365 hasConceptScore W1978331365C121608353 @default.
• W1978331365 hasConceptScore W1978331365C126322002 @default.
• W1978331365 hasConceptScore W1978331365C143998085 @default.
• W1978331365 hasConceptScore W1978331365C2776694085 @default.
• W1978331365 hasConceptScore W1978331365C2776755627 @default.
• W1978331365 hasConceptScore W1978331365C2776802502 @default.
• W1978331365 hasConceptScore W1978331365C2778239845 @default.
• W1978331365 hasConceptScore W1978331365C2780835546 @default.
• W1978331365 hasConceptScore W1978331365C2781413609 @default.
• W1978331365 hasConceptScore W1978331365C2781451048 @default.
• W1978331365 hasConceptScore W1978331365C530470458 @default.
• W1978331365 hasConceptScore W1978331365C71924100 @default.
• W1978331365 hasIssue "16" @default.
• W1978331365 hasLocation W19783313651 @default.
• W1978331365 hasLocation W19783313652 @default.
• W1978331365 hasOpenAccess W1978331365 @default.
• W1978331365 hasPrimaryLocation W19783313651 @default.
• W1978331365 hasRelatedWork W2020150632 @default.
• W1978331365 hasRelatedWork W2078074588 @default.
• W1978331365 hasRelatedWork W2153230751 @default.

• next